MedTrace Logo

A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B

NCT03357822 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2018-04-25

No results posted yet for this study

Summary

The aim of the prospective real-world study is to evaluate whether sequential combination therapy with pegylated interferon plus entecavir/tenofovir could induce higher rates of HBsAg loss in nucleoside-treated patients with chronic hepatitis B compared to continuous nucleoside treatment.

Conditions

Interventions

DRUG

Pegylated interferon

180ug Pegylated interferon is injected subcutaneously once a week

DRUG

Entecavir

0.5mg entecavir is orally taken every day

DRUG

Tenofovir disoproxil fumarate

300mg tenofovir is orally taken every day

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Qin Ning · Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-25
Primary Completion
2022-01-25
Completion
2022-07-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03357822 on ClinicalTrials.gov